HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability-Reference-Cited by-同舟云学术

HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability

Published:2020-12-14 Issue:24 Volume:63 Page:15906-15945
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Elwaie Tamer A.¹²,Abbas Safinaz E.²,Aly Enayat I.²,George Riham F.²,Ali Hamdy¹,Kraiouchkine Nikolai³,Abdelwahed Khaldoun S.⁴,Fandy Tamer E.⁵,El Sayed Khalid A.⁴^ORCID,Abd Elmageed Zakaria Y.¹⁶,Ali Hamed I.¹^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, College Station, Kingsville, Texas 78363, United States

2. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt

3. Department of Physical and Environmental Sciences, Texas A&M University, Corpus Christi, Texas 78412, United States

4. School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, Louisiana 71201, United States

5. Department of Pharmaceutical & Administrative Sciences, School of Pharmacy, University of Charleston, Charleston, West Virginia 25304, United States

6. Department of Pharmacology, Edward Via College of Osteopathic Medicine, University of Louisiana at Monroe, Monroe, Louisiana 71203, United States

Funder

Texas A and M University

Ministry of Higher Education

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01647

Reference119 articles.

1. The Global Burden of Cancer 2013